Cathy B Moelans

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2390974/publications.pdf

Version: 2024-02-01

70	1,890	257450 24	276875 41
papers	citations	h-index	g-index

72	72	72	3292
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	OUP accepted manuscript. Clinical Chemistry, 2022, , .	3.2	5
2	Nipple Aspirate Fluid at a Glance. Cancers, 2022, 14, 159.	3.7	7
3	Patient-centered research: how do women tolerate nipple fluid aspiration as a potential screening tool for breast cancer?. BMC Cancer, 2022, 22, .	2.6	0
4	Genomic copy number alterations as biomarkers for triple negative pregnancy-associated breast cancer. Cellular Oncology (Dordrecht), 2022, 45, 591-600.	4.4	3
5	Heterogeneity in Signaling Pathway Activity within Primary and between Primary and Metastatic Breast Cancer. Cancers, 2021, 13, 1345.	3.7	2
6	The changing microRNA landscape by color and cloudiness: a cautionary tale for nipple aspirate fluid biomarker analysis. Cellular Oncology (Dordrecht), 2021, 44, 1339-1349.	4.4	4
7	Lessons Learned from Setting Up a Prospective, Longitudinal, Multicenter Study with Women at High Risk for Breast Cancer. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 441-449.	2.5	10
8	The Physiological MicroRNA Landscape in Nipple Aspirate Fluid: Differences and Similarities with Breast Tissue, Breast Milk, Plasma and Serum. International Journal of Molecular Sciences, 2020, 21, 8466.	4.1	4
9	Methylation Profile of X-Chromosomeâ€“Related Genes in Male Breast Cancer. Frontiers in Oncology, 2020, 10, 784.	2.8	8
10	Application of Nipple Aspirate Fluid miRNA Profiles for Early Breast Cancer Detection and Management. International Journal of Molecular Sciences, 2019, 20, 5814.	4.1	6
11	Frequent discordance in PD-1 and PD-L1 expression between primary breast tumors and their matched distant metastases. Clinical and Experimental Metastasis, 2019, 36, 29-37.	3.3	47
12	Promoter hypermethylation in ductal carcinoma in situ of the male breast. Endocrine-Related Cancer, 2019, 26, 575-584.	3.1	8
13	The molecular genetic make-up of male breast cancer. Endocrine-Related Cancer, 2019, 26, 779-794.	3.1	27
14	Mutation Profiling of Key Cancer Genes in Primary Breast Cancers and Their Distant Metastases. Cancer Research, 2018, 78, 3112-3121.	0.9	57
15	Copy number profiling of oncogenes in ductal carcinoma in situ of the male breast. Endocrine-Related Cancer, 2018, 25, 173-184.	3.1	6
16	Receptor Conversion in Distant Breast Cancer Metastases: A Systematic Review and Meta-analysis. Journal of the National Cancer Institute, 2018, 110, 568-580.	6.3	198
17	Molecular profile of nasopharyngeal carcinoma: analysing tumour suppressor gene promoter hypermethylation by multiplex ligation-dependent probe amplification. Journal of Clinical Pathology, 2018, 71, 351-359.	2.0	8
18	Methylation-Specific Multiplex Ligation-Dependent Probe Amplification (MS-MLPA). Methods in Molecular Biology, 2018, 1708, 537-549.	0.9	22

#	Article	IF	Citations
19	Response to A. Matikas et al.. Journal of the National Cancer Institute, 2018, 110, 1282-1283.	6.3	0
20	PD-1 and PD-L1 Expression in Male Breast Cancer in Comparison with Female Breast Cancer. Targeted Oncology, 2018, 13, 769-777.	3.6	10
21	Role of columnar cell lesions in breast carcinogenesis: analysis of chromosome 16 copy number changes by multiplex ligation-dependent probe amplification. Modern Pathology, 2018, 31, 1816-1833.	5.5	10
22	<scp>FOXA</scp>1 levels are decreased in pleural breast cancer metastases after adjuvant endocrine therapy, and this is associated with poor outcome. Molecular Oncology, 2018, 12, 1884-1894.	4.6	19
23	Differences in cancer gene copy number alterations between Epsteinâ€Barr virusâ€positive and Epsteinâ€Barr virusâ€negative nasopharyngeal carcinoma. Head and Neck, 2018, 40, 1986-1998.	2.0	3
24	Copy number changes at 8p11-12 predict adverse clinical outcome and chemo- and radiotherapy response in breast cancer. Oncotarget, 2018, 9, 17078-17092.	1.8	14
25	Global transcriptional analysis identifies a novel role for SOX4 in tumor-induced angiogenesis. ELife, 2018, 7, .	6.0	32
26	Optimal Fixation Conditions and DNA Extraction Methods for MLPA Analysis on FFPE Tissue-Derived DNA. American Journal of Clinical Pathology, 2017, 147, aqw205.	0.7	22
27	A Novel Diagnostic Tool for Selecting Patients With Mesenchymal-Type Colon Cancer Reveals Intratumor Subtype Heterogeneity. Journal of the National Cancer Institute, 2017, 109, .	6.3	30
28	Loss of steroid hormone receptors is common in malignant pleural and peritoneal effusions of breast cancer patients treated with endocrine therapy. Oncotarget, 2017, 8, 55550-55561.	1.8	14
29	Progressive APOBEC3B mRNA expression in distant breast cancer metastases. PLoS ONE, 2017, 12, e0171343.	2.5	31
30	Unravelling site-specific breast cancer metastasis: a microRNA expression profiling study. Oncotarget, 2017, 8, 3111-3123.	1.8	24
31	Influence of decalcification procedures on immunohistochemistry and molecular pathology in breast cancer. Modern Pathology, 2016, 29, 1460-1470.	5.5	62
32	DNA promoter hypermethylation in nipple fluid: a potential tool for early breast cancer detection. Oncotarget, 2016, 7, 24778-24791.	1.8	24
33	Clinical relevance of copy number profiling in oral and oropharyngeal squamous cell carcinoma. Cancer Medicine, 2015, 4, 1525-1535.	2.8	37
34	Chromosome 17 copy number changes in male breast cancer. Cellular Oncology (Dordrecht), 2015, 38, 237-245.	4.4	12
35	Promoter hypermethylation profiling of distant breast cancer metastases. Breast Cancer Research and Treatment, 2015, 151, 41-55.	2.5	11
36	Methylation biomarkers for pleomorphic lobular breast cancer - a short report. Cellular Oncology (Dordrecht), 2015, 38, 397-405.	4.4	10

#	Article	IF	Citations
37	Upregulation of Claudin-4, CAIX and GLUT-1 in distant breast cancer metastases. BMC Cancer, 2014, 14, 864.	2.6	32
38	CEP17 copy number increase does not indicate polysomy 17. Journal of Clinical Pathology, 2014, 67, 454.1-455.	2.0	7
39	Genomic evolution from primary breast carcinoma to distant metastasis: Few copy number changes of breast cancer related genes. Cancer Letters, 2014, 344, 138-146.	7.2	34
40	Promoter hypermethylation using 24-gene array in early head and neck cancer. Epigenetics, 2014, 9, 1220-1227.	2.7	24
41	Validation of DNA promoter hypermethylation biomarkers in breast cancer â€" a short report. Cellular Oncology (Dordrecht), 2014, 37, 297-303.	4.4	37
42	Clonal intratumor heterogeneity of promoter hypermethylation in breast cancer by MS-MLPA. Modern Pathology, 2014, 27, 869-874.	5.5	20
43	Analysis of copy number changes on chromosome 16q in male breast cancer by multiplex ligation-dependent probe amplification. Modern Pathology, 2013, 26, 1461-1467.	5.5	19
44	Added Value of HER-2 Amplification Testing by Multiplex Ligation-Dependent Probe Amplification in Invasive Breast Cancer. PLoS ONE, 2013, 8, e82018.	2.5	2
45	ESR1 Amplification in Breast Cancer by Optimized RNase FISH: Frequent but Low-Level and Heterogeneous. PLoS ONE, 2013, 8, e84189.	2.5	14
46	Promoter hypermethylation in male breast cancer: analysis by multiplex ligation-dependent probe amplification. Breast Cancer Research, 2012, 14, R101.	5.0	49
47	Oncogene amplification in male breast cancer: analysis by multiplex ligation-dependent probe amplification. Breast Cancer Research and Treatment, 2012, 135, 49-58.	2.5	53
48	Prognostic value of estrogen receptor Î± and progesterone receptor conversion in distant breast cancer metastases. Cancer, 2012, 118, 4929-4935.	4.1	81
49	Formaldehyde substitute fixatives: effects on nucleic acid preservation. Journal of Clinical Pathology, 2011, 64, 960-967.	2.0	48
50	Formaldehyde Substitute Fixatives. American Journal of Clinical Pathology, 2011, 136, 548-556.	0.7	48
51	Implications of rarity of chromosome 17 polysomy in breast cancer. Lancet Oncology, The, 2011, 12, 1087-1089.	10.7	16
52	HER-2/neuTesting and Therapy in Gastroesophageal Adenocarcinoma. Pathology Research International, 2011, 2011, 1-10.	1.4	35
53	Low frequency of HER2 amplification and overexpression in early onset gastric cancer. Cellular Oncology (Dordrecht), 2011, 34, 89-95.	4.4	41
54	Molecular differences between ductal carcinoma in situ and adjacent invasive breast carcinoma: a multiplex ligation-dependent probe amplification study. Cellular Oncology (Dordrecht), 2011, 34, 475-482.	4.4	38

#	Article	IF	Citations
55	ESR1 amplification is rare in breast cancer and is associated with high grade and high proliferation: a multiplex ligation-dependent probe amplification study. Cellular Oncology (Dordrecht), 2011, 34, 489-494.	4.4	18
56	Frequent promoter hypermethylation of BRCA2, CDH13, MSH6, PAX5, PAX6 and WT1 in ductal carcinoma in situ and invasive breast cancer. Journal of Pathology, 2011, 225, 222-231.	4.5	118
57	Amplification Testing in Breast Cancer by Multiplex Ligation-Dependent Probe Amplification of Microdissected Tissue. Methods in Molecular Biology, 2011, 755, 107-118.	0.9	3
58	Absence of chromosome 17 polysomy in breast cancer: analysis by CEP17 chromogenic in situ hybridization and multiplex ligation-dependent probe amplification. Breast Cancer Research and Treatment, 2010, 120, 1-7.	2.5	104
59	Molecular Differences between Ductal CarcinomaIn Situand Adjacent Invasive Breast Carcinoma: A Multiplex Ligation-Dependent Probe Amplification Study. Analytical Cellular Pathology, 2010, 33, 165-173.	1.4	21
60	ESR1 Amplification is Rare in Breast Cancer and is Associated with High Grade and High Proliferation: A Multiplex Ligation-Dependent Probe Amplification Study. Analytical Cellular Pathology, 2010, 33, 13-18.	1.4	16
61	Molecular profiling of invasive breast cancer by multiplex ligation-dependent probe amplification-based copy number analysis of tumor suppressor and oncogenes. Modern Pathology, 2010, 23, 1029-1039.	5.5	90
62	Simultaneous detection of TOP2A and HER2 gene amplification by multiplex ligation-dependent probe amplification in breast cancer. Modern Pathology, 2010, 23, 62-70.	5.5	38
63	Molecular differences between ductal carcinoma in situ and adjacent invasive breast carcinoma: a multiplex ligation-dependent probe amplification study. Analytical Cellular Pathology, 2010, 33, 165-73.	1.4	16
64	Validation of a Fully Automated HER2 Staining Kit in Breast Cancer. Analytical Cellular Pathology, 2010, 32, 149-155.	1.4	1
65	Multiplex Ligation-Dependent Probe Amplification to Detect HER2 Amplification in Breast Cancer: New Insights in Optimal Cut-Off Value. Analytical Cellular Pathology, 2010, 32, 311-312.	1.4	1
66	ESR1 amplification is rare in breast cancer and is associated with high grade and high proliferation: a multiplex ligation-dependent probe amplification study. Analytical Cellular Pathology, 2010, 33, 13-8.	1.4	10
67	Validation of a fully automated HER2 staining kit in breast cancer. Cellular Oncology, 2010, 32, 149-55.	1.9	7
68	HER-2/neu amplification testing in breast cancer by Multiplex Ligation-dependent Probe Amplification: influence of manual- and laser microdissection. BMC Cancer, 2009, 9, 4.	2.6	32
69	HER-2/neu amplification testing in breast cancer by multiplex ligation-dependent probe amplification in comparison with immunohistochemistry and in situ hybridization. Cellular Oncology, 2009, 31, 1-10.	1.9	28
70	HER-2/neu Amplification Testing in Breast Cancer by Multiplex Ligation-Dependent Probe Amplification in Comparison with Immunohistochemistry and In Situ Hybridization. Analytical Cellular Pathology, 2009, 31, 1-10.	1.4	2